REG - Integrated Diag Hdgs - Update on Treasury Shares Removal Process

Integrated Diagnostics HoldingsAnnouncement

06/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240906:nRSF1497Da&default-theme=true

RNS Number : 1497D  Integrated Diagnostics Holdings PLC  06 September 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO
SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

 

 

Integrated Diagnostics Holdings plc

 

 

Update on Treasury Shares Removal Process

 

6 September 2024

 

Integrated Diagnostics Holdings plc ("IDH" or the "Company") refers to the
Company's announcement on 27 August 2024 (the "Buyback Announcement") in
relation to the share buyback under the Egyptian Exchange's special operations
market (OPR) and the Company's repurchase of 18,673,728 EGX Shares (as defined
in the Buyback Announcement) (the "Repurchased Shares") on 26 August 2024
pursuant to that share buyback. As reflected in that announcement, the Company
had previously expected that the removal of the Repurchased Shares from Misr
for Central Clearing, Depository and Registry (MCDR) to be held in the name of
the Company as treasury shares (the "Removal Process") would complete on or
about 2 September 2024. This process is underway but will take longer to
complete than had originally been expected and is now expected to complete
later in September 2024. The Company will release a further announcement once
the Removal Process has been completed.

 

For further information please contact:

 

Integrated Diagnostics Holdings plc

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 |    tarek.yehia@idhcorp.com
(mailto:tarek.yehia@idhcorp.com)

 

Company Secretary

Company Matters

IDHLondon@linkgroup.co.uk (mailto:IDHLondon@linkgroup.co.uk)

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

 

IDH is a leading diagnostics services provider in the Middle East and Africa
offering a broad range of clinical pathology and radiology tests to patients
in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core
brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as
Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both
in Sudan), and Biolab KSA (Saudi Arabia).  With over 40 years of
experience, a long track record for quality and safety has earned the Company
a trusted reputation, as well as internationally recognised accreditations for
its portfolio of over 3 ,000 diagnostics tests. From its base
of 601 branches as of 31 December 2023, IDH served over 8. 5 million
patients and performed more than 36.1 million tests in 2023.  IDH will
continue to add laboratories through a Hub, Spoke and Spike business model
that provides a scalable platform for efficient expansion.  Beyond organic
growth, the Group targets expansion in appealing markets,
including acquisitions in the Middle Eastern, African, and East Asian
markets where its model is well-suited to capitalise on similar healthcare and
consumer trends and capture a significant share of fragmented markets.  IDH
is a Jersey-registered entity whose Shares are admitted to the equity shares
(transition) category (previously, the standard listing segment) of the
Official List of the UK Financial Conduct Authority and admitted to trading on
the main market for listed securities of the London Stock Exchange since May
2015 (ticker: IDHC).

 

Learn more at idhcorp.com (http://idhcorp.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKPBNOBKDCCK